NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 1 FDA
NCT03653507 2026-02-06GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 1 FDA
NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT02864992 2025-12-23Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)EMD SeronoPhase 2 Active not recruiting337 enrolled 13 charts 2 FDA
NCT03539536 2025-11-05Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerAbbViePhase 2 Active not recruiting270 enrolled 1 FDA
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT03785249 2025-09-30Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Mirati Therapeutics Inc.Phase 1/2 Active not recruiting731 enrolled 2 FDA
NCT03470922 2025-09-09RELATIVITY-047Bristol-Myers SquibbPhase 2/3 Active not recruiting714 enrolled 17 charts 1 FDA
NCT04607421 2025-08-14A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPfizerPhase 3 Active not recruiting831 enrolled 2 FDA
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA